Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus

References

• IDF. IDF diabetes atlas 2015. Int Diabetes Fed. 2015.
   Google Scholar
• Gujral UP, Pradeepa R, Weber MB, Narayan KMV, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann. N. Y. Acad. Sci. 2013;1281(1):51–63. doi:10.1111/j.1749-6632.2012.06838.x
   PubMed Web of Science ®Google Scholar
• Phillips LK, Prins JB. Update on incretin hormones.. Ann N Y Acad Sci. 2011;00:1–20.
   Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–520. doi:10.1172/JCI990
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187–215. doi:10.1210/er.2011-1052
   PubMed Web of Science ®Google Scholar
• Campbell IW, Day C. Sitagliptin - Enhancing incretin action. Br. J. Diabetes Vasc. Dis. 2007;7(3):134–139. doi:10.1177/14746514070070030601
   Google Scholar
• Cernea S, Itamar RAZ. Therapy in the early stage: incretins. Diabetes Care. 2011;34(SUPPL):2. doi:10.2337/dc11-s223
   PubMedGoogle Scholar
• Rodbard HW, Jellinger P, Davidson J, et al. Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 2009;15(6):540–559. doi:10.4158/EP.15.6.540
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23(6):1329–1339. doi:10.1185/030079907X188152
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37:S14.
   PubMed Web of Science ®Google Scholar
• Cai X, Han X, Luo Y, Ji L. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis. J Diabetes. 2015;7(3):347–359. doi:10.1111/1753-0407.12196
   PubMed Web of Science ®Google Scholar
• Mohan V, Yang W, Son H-Y, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res. Clin. Pract. 2009;83(1):106–116. doi:10.1016/j.diabres.2008.10.009
   PubMed Web of Science ®Google Scholar
• Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2008;79(2):291–298. doi:10.1016/j.diabres.2007.08.021
   PubMed Web of Science ®Google Scholar
• Sakaoto Y, Oyama J, Ikeda H, et al. Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol. 2013;12(35):1–9. doi:10.1186/1475-2840-12-1
   PubMedGoogle Scholar
• Shigematsu E, Yamakawa T, Kadonosono K, et al. Effect of sitagliptin on lipid profile in patients with type 2 Diabetes Mellitus. J Clin Med Res. 2014;6(5):327–335. doi:10.14740/jocmr1889w
   PubMedGoogle Scholar
• Husain M, Atif MA, Tunio AG, et al. Effect of Sitagliptin on glycemic control, bodyweight, blood pressure and serum lipid profile in type 2 diabetic hyperlipidemic patients. J Ayub Med Coll Abbottabad. 2016;28(2):369–372.
   PubMedGoogle Scholar
• Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(10):1556–1568. doi:10.1016/j.clinthera.2006.10.007
   PubMed Web of Science ®Google Scholar
• Steinberg H, Anderson MS, Musliner T, et al. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. Vasc Health Risk Manag. 2013;9:273–282. doi:10.2147/VHRM.S44330
   PubMedGoogle Scholar
• Mells JE, Ananis FA. The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis. 2013;33(4):343–357. doi:10.1055/s-0033-1358527
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987. doi:10.2337/dc07-0627
   PubMed Web of Science ®Google Scholar
• Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171–180. doi:10.1111/j.1742-1241.2006.01246.x
   PubMed Web of Science ®Google Scholar
• Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obes. Metab. 2008;10(10):959–969. doi:10.1111/j.1463-1326.2007.00839.x
   PubMed Web of Science ®Google Scholar
• Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470–512. doi:10.1124/pr.108.000604
   PubMed Web of Science ®Google Scholar
• Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56(4):728–733. doi:10.1161/HYPERTENSIONAHA.110.156554
   PubMed Web of Science ®Google Scholar
• Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, Brubaker PL. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinology. 2012;153(2):564–573. doi:10.1210/en.2011-1732
   PubMed Web of Science ®Google Scholar
• Xu L, Man CD, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: A model-based approach. Diabetes Obes Metab. 2008;10(12):1212–1220.
   PubMedGoogle Scholar
• Conarello SL, Li Z, Ronan J, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2003;100(11):6825–6830. doi:10.1073/pnas.0631828100
   PubMed Web of Science ®Google Scholar
• Mu J, Woods J, Zhou Y-P, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55(6):1695–1704. doi:10.2337/db05-1602
   PubMed Web of Science ®Google Scholar
• Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and “isoglycemic” intravenous glucose. Diabetes. 2014;63(2):663–674. doi:10.2337/db13-0805
   PubMed Web of Science ®Google Scholar
• Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein P. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):186–193. doi:10.1111/j.1463-1326.2006.00691.x
   PubMed Web of Science ®Google Scholar
• He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J. Clin. Pharmacol. 2007;47(5):633–641. doi:10.1177/0091270006299137
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564–2571. doi:10.1007/s00125-006-0416-z
   PubMed Web of Science ®Google Scholar
• Wang Y, Perfetti R, Greig NH, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J. Clin. Invest. 1997;99(12):2883–2889. doi:10.1172/JCI119482
   PubMed Web of Science ®Google Scholar
• Doyle ME, Egan JM. Glucagon-like peptide-1. Recent Prog Horm Res. 2001;56(1):377–399. doi:10.1210/rp.56.1.377
   PubMedGoogle Scholar